DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Litifilimab

Generic Name: Litifilimab

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways

Phase 1

Recruiting

Posted: 2024/12/19

Sponsor:Biogen

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

Phase 2

Recruiting

Posted: 2022/09/08

Sponsor:Biogen

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Phase 3

Posted: 2022/04/29

Sponsor:Biogen

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Phase 3

Recruiting

Posted: 2021/07/14

Sponsor:Biogen

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Phase 3

Recruiting

Posted: 2021/05/20

Sponsor:Biogen

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Biogen Secures $250M from Royalty Pharma to Advance Lupus Antibody into Phase III Trials

4 months ago

Biogen has entered into a strategic funding agreement with Royalty Pharma, securing $250 million over six quarters to advance litifilimab, a promising lupus treatment, into Phase III development.

Deucravacitinib Demonstrates Superior Efficacy in Cutaneous Lupus Erythematosus Treatment

5 months ago

A recent study indicates that deucravacitinib is more effective than anifrolumab and litifilimab in treating cutaneous lupus erythematosus (CLE).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy